Cenicriviroc
| CAS No. | 497223-25-3 | Cat. No. | BCP23849 |
| Name | Cenicriviroc | ||
| Synonyms | TAK-652; TAK652; TAK 652; TBR-652; TBR 652; TBR652; | ||
| Formula | C41H52N4O4S | M. Wt | 696.95 |
| Description | Cenicriviroc, also known as TAK-652 and TBR-652, is an experimental drug candidate for the treatment of HIV infection. It is being developed by Takeda Pharmaceutical and Tobira Therapeutics. Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell. Inhibition of CCR2 may have an anti-inflammatory effect. | ||
| Pathways | GPCR/G Protein | ||
| Targets | CCR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.